NCT00381693View on ClinicalTrials.gov

Azacitidine in Treating Patients With Myelofibrosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2009

Conditions
Chronic Myeloproliferative DisordersSecondary Myelofibrosis
Interventions
DRUG

azacitidine

Trial Locations (2)

55905

Mayo Clinic, Rochester

Unknown

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00381693 - Azacitidine in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter